Two Arthritis Medicines Compared for Rheumatoid Arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares two newer oral medications—tofacitinib and upadacitinib—to see which works better and is safer when added to methotrexate for rheumatoid arthritis. Both medicines help calm the immune system's attack on joints.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have rheumatoid arthritis only (not lupus, psoriatic arthritis, or ankylosing spondylitis)
- You have not taken biologic drugs (like TNF inhibitors) in the last 3 months
- You do not have a current serious infection, active tuberculosis, or a history of frequent infections
- You have no cancer history in the last 5 years and are not currently on chemotherapy or radiotherapy
- Your liver, kidney, and blood cell counts are healthy enough for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two oral medications, iguratimod and tofacitinib (Xeljanz), to see if they work better together for rheumatoid arthritis that is not well controlled on current treatment.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
This study tests whether the medication upadacitinib (Rinvoq) works similarly for psoriatic arthritis and rheumatoid arthritis. Participants will have ultrasound imaging to track joint inflammation while taking upadacitinib.
This trial tests taking a JAK inhibitor (a type of pill that helps calm inflammation in rheumatoid arthritis) by mouth. It aims to see how well it works and if it's safe for people with RA who need this kind of medicine.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.